Quanterix Corporation: Business Overview, Financials & Competitive Analysis
Quanterix Corporation scores 6/10 on the AskCyborg Cyborg Score (Solid). Emerging leader in ultra-sensitive biomarker detection with strong revenue growth trajectory, strategic FDA submissions, and expanding clinical applications positioning it for meaningful market impact in precision diagnostics. Quanterix generated revenue of $137.42 million in 2024, increasing 12.30% year-over-year, with growing strategic momentum in Alzheimer's and biomarker diagnostics. However, losses were.
What is Quanterix Corporation's industry? Quanterix Corporation (quanterix.com) operates in Life Sciences / In-Vitro Diagnostics / Biomarker Detection Technology. AskCyborg classifies Quanterix Corporation under Life Sciences / In-Vitro Diagnostics / Biomarker Detection Technology in its company registry.
Quanterix is a life sciences company that develops and markets digital immunoassay platforms advancing precision health for life sciences research and diagnostics across North America, Europe, Middle East, Africa, and...
Cyborg Score thesis
Emerging leader in ultra-sensitive biomarker detection with strong revenue growth trajectory, strategic FDA submissions, and...
Read the full analyst-debate transcript →Get the Latest Quanterix Corporation Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeQuanterix Corporation Overview
Pro stress-test →Quanterix is a life sciences company that develops and markets digital immunoassay platforms advancing precision health for life sciences research and diagnostics across North America, Europe, Middle East, Africa, and Asia Pacific regions. The company develops ultra-sensitive detection systems for use in research and in-vitro diagnostics.
Strategic Profile
Pro stress-test →The company operates a consumable-based revenue model providing recurring revenue and high margins as the installed base of Simoa instruments grows. The company primarily operates in neurology, oncology, immunology, and inflammation, with focus on selling to academic/governmental research institutions, pharmaceutical, biotechnology, and contract research companies through direct sales and distributors.
Competitive Landscape
Pro stress-test →According to 3 analysts, the average rating for QTRX is "Hold" with 12-month stock price target of $10.33 representing 35.74% upside from latest price. Quanterix competes in the biomarker diagnostics and ultra-sensitive detection space against established in-vitro diagnostics companies and emerging precision health platforms.
Industry Context
Quanterix Corporation operates in Life Sciences / In-Vitro Diagnostics / Biomarker Detection Technology.
Key facts
Founded: 2007 · Headquarters: Billerica, Massachusetts, US · Revenue: $137.4M (2024) · Market cap: $0.22B